13 Set It is called durvalumab (Cancer Killer)
This especialy when you may be lost hope or it is difficult to find a solution. This is the case when you are suffering from a locally advanced and unoperable stage III lung cancer.
Or when no improvement is achieved with platinum-standard platelet-based chemotherapy and radiotherapy (CRT).
A widespread tumor(lung)
The lung is one of the most difficult tumors to treat, and with a high index of mortality. It is a widespread disease, and despite being more affected by male subjects (one in 10) than female subjects (one out of 37).
Last year there was a decrease, instead of an increase between the female audience: According to AIOM data, in 2016 13,500 cases were diagnosed only among women. The cases among men were 27,800.
Lung cancer is ranked second among the most common malignant tumors (15%) after prostate cancer, and third place among the most diagnosed among women (6%) after breast and colon rectum.
In the general population, lung cancer is ranked third among the five most common tumors after the breast and colon rectum. They follow prostate and bladder.
In males in the age range of 50-69, lung cancer is the second in the incidence after the prostate, while women in the age group are in the sixth (0-49 years) or fourth place ( 50-69 years).
In the general population, lung cancer is also the first cause of death (19%), while in particular it is 26% -30% of men in all age groups and 9% -14% of women depending on age groups.
Hence the importance of finding more effective treatments in fighting this killer cancer, including reducing or relieving recurrences.
The effectiveness of new therapies
To ensure more effective therapies and thus better results, researchers have focused recently on those treatments that may someday become an alternative to traditional therapies.
For example, in substitution for radiotherapy chemotherapy, which, on the one hand, are effective, on the other, have heavy side effects.
One of these treatments was presented at Esmo 2017 Congress in Madrid, and the data presented as an interim analysis of Phase III PACIFIC study follows the recent recognition of Durvalumab as an innovative therapy by the FDA.
Specifically, Durvalumab has been shown to have promoted statistically and clinically significant improvement in PFS compared to standard therapy in locally advanced, non-operable stage III lung cancer patients.
Patients who did not demonstrate improvements with platinum-standard chemotherapy combined with radiotherapy (CRT).
The results presented at the European Society of Medical Oncology (ESMO) are part of the Phase III PACIFIC trial. The use of durvalumab as monotherapy demonstrated an improvement in PFS over 11 months in patients treated with placebo.
Improvement of PFS with durvalumab was observed in all pre-specified subgroups, including the expression of PD-L1 – a protein produced by tumor cells.
In addition, durvalumab-treated patients had a lower incidence of new metastases than patients treated with placebo. Strong of these results, now PACIFIC experimentation continues to evaluate the other primary endpoint, ie overall survival.
“Phase III PACIFIC results are incredibly encouraging for a population of patients who have not yet had therapeutic options to date,” says Filippo de Marinis, Director of the Toracic Oncology Division at the European Oncology Institute (IEO) in Milan.
of first-on-one therapy to achieve improvement in progression-free survival, durvalumab demonstrates a clear potential for becoming the new standard therapy offering hope to increase the healing rate in this type of NSCLC (non-small cell lung cancer ), which did not demonstrate any improvement after chemotherapy. “